Targeted next-generation sequencing of FNA-derived DNA in pancreatic cancer. Issue 2 (26th September 2016)

• Record Type: Journal Article
• Authors: Sibinga Mulder, Babs G; Mieog, J Sven D; Handgraaf, Henricus J M; Farina Sarasqueta, Arantza; Vasen, Hans F A; Potjer, Thomas P; Swijnenburg, Rutger-Jan; Luelmo, Saskia A C; Feshtali, Shirin; Inderson, Akin; Vahrmeijer, Alexander L; Bonsing, Bert A; van Wezel, Tom; Morreau, Hans
• Is Part Of: Journal of clinical pathology. Volume 70:Issue 2(2017)
• Page Start: 174
• Page End: 178
• Publication Date: 2016-09-26
• Subjects: DNA -- PANCREAS -- DIAGNOSTICS -- CANCER -- MOLECULAR PATHOLOGY; Pathology -- Periodicals; Pathology, Molecular -- Periodicals; 616.0705
• DOI: 10.1136/jclinpath-2016-203928
• Languages: English
• ISSNs: 0021-9746

Abstract

Abstract : To improve the diagnostic value of fine-needle aspiration (FNA)-derived material, we perform targeted next-generation sequencing (NGS) in patients with a suspect lesion of the pancreas. The NGS analysis can lead to a change in the treatment plan or supports inconclusive or uncertain cytology results. We describe the advantages of NGS using one particular patient with a recurrent pancreatic lesion 7 years after resection of a pancreatic ductal adenocarcinoma (PDAC). Our NGS analysis revealed the presence of a presumed second primary cancer in the pancreatic remnant, which led to a change in treatment: resection with curative intend instead of palliation. Additionally, NGS identified an unexpected germline CDKN2A 19-base pair deletion, which predisposed the patient to developing PDAC. Preoperative NGS analysis of FNA-derived DNA can help identify patients at risk for developing PDAC and define future therapeutic options.